cancer

Leveraging the Microbiome to Break Down Tumor Resistance

Mat Robinson and Mark Tangney discuss how enhancing the efficacy of immune checkpoint inhibitors improves patient outcomes.

This webinar will be hosted live and available on-demand

 Thursday, September 15th, 2022 
11:00 AM - 12:30 PM Eastern Time (8:00 AM PDT / 4:00 PM GMT)

Immunotherapies, such as immune checkpoint inhibitors, have been a game changer in treating cancer patients. However, despite significant treatment advances, many patients fail to respond therapy. Researchers are exploring factors that influence individual differences in treatment response to predict which patients will respond to immunotherapy. The gut microbiome has emerged as an important immune response modulator and scientists can leverage this community to overcome tumor resistance to immune checkpoint inhibitors.

In this webinar brought to you by PerkinElmer, Mat Robinson and Mark Tangney will explore the emerging role of microbiome precision medicine in immuno-oncology, including the use of fecal microbiota transplantation as a novel adjuvant to immune checkpoint therapy in cancer patients.

Topics to be covered

  • How the immune response is linked to gut microbiome composition
  • Why fecal transplants enhance immune checkpoint treatment efficacy
  • How microbiome signatures provide a predictive biomarker to stratify patient responders to checkpoint therapy


Mat Robinson, PhD
Vice President, Translational Biology
Microbiotica Limited

Mark Tangney, PhD
Principle Investigator
University College Cork

Sponsored by